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Abstract
Objective: Dopamine D2-like receptors – mainly dopamine D2 receptors
(D2R) and dopamine D3 receptors (D3R) – are believed to be greatly involved
in the pathology of Parkinson disease (PD) progression. However, these recep-
tors have not been precisely examined in PD patients. Our aim was to quantita-
tively calculate the exact densities of dopamine D1 receptors (D1R), D2R, and
D3R in control, Alzheimer disease (AD), and Lewy body disease (LBD) patients
(including PD, Dementia with Lewy bodies, and Parkinson disease dementia);
and analyze the relationship between dopamine receptors and clinical PD mani-
festations. Methods: We analyzed the densities of D1R, D2R, and D3R in the
striatum and substantia nigra (SN) using a novel quantitative autoradiography
procedure previously developed by our group. We also examined the expression
of D2R and D3R mRNA in the striatum by in situ hybridization. Results: The
results showed that although no differences of striatal D1R were found among
all groups; D2R was significantly decreased in the striatum of PD patients when
compared with control and AD patients. Some clinical manifestations: age of
onset, PD stage, dopamine responsiveness, and survival time after onset;
showed a better correlation with striatal D1R + D3R densities combined com-
pared to D1R or D3R alone. Interpretation: There is a possibility that we may
infer the results in diagnosis, treatment, and prognosis of PD by detecting
D1R + D3R as opposed to using dopamine D1 or D3 receptors alone. This is
especially true for elderly patients with low D2R expression as is common in
this disease.
Introduction
Parkinson disease (PD) – one common type of Lewy
body disease – is the second most common neurodegen-
erative disease in people over 60 years old. PD may be
difficult to distinguish from other similar conditions, par-
ticularly in the early stage of the disease due to overlap-
ping symptom manifestations. Levodopa (L-Dopa)
remains the most effective pharmacologic treatment for
PD currently available. However, as the disease progresses,
doses of L-Dopa may cause adverse side effects such as
dyskinesia and motor fluctuations. Alternatively, dopa-
mine receptors (DRs) provide another potential target for
pharmacotherapy. DRs are divided into 2 main groups:
the dopamine D1-like receptors (D1Rs) and the dopa-
mine D2-like receptors (D2Rs). Generally speaking, D1Rs
(including D1R and D5R) couple to Gαs/olf and induce
production of cyclic adenosine monophosphate (cAMP)
and the activation of protein kinase A (PKA). D2Rs (in-
cluding D2R, D3R, and D4R) activate Gαi/o and inhibit
cAMP production.1 Dopamine (DA) exerts its effect
mainly through D1R, D2R, and D3R in the striatum. The
quantification of these receptors may help advance early
detection and provide a metric of target engagement.
Unfortunately, most of the research on this topic uses
animal models and only a few studies have unveiled the
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distribution of D2R and D3R in the human brain via
Positron Emission Tomography (PET). Existing PET trac-
ers do not distinguish D2R from D3R because they share
79% sequence homology.2 Therefore, in this study, we
used a newly developed method previously published by
our group to accurately quantify the distribution of these
receptors. This method utilizes two tracers in postmortem
human brain slices to map the precise D2R and D3R dis-
tribution in the striatum and SN of control, Alzheimer’s
disease (AD), and PD patients. After the density of DRs
was obtained, we correlated the DR densities with clini-
cally observed symptomatic and therapeutic features of
these patients.
Cognitive impairment appears in most PD patients cat-
egorized as either early-onset dementia, Dementia with
Lewy bodies (DLB), or later onset dementia called Parkin-
son disease dementia (PDD) – these 3 distinctions can be
broadly categorized together as a Lewy body disease
(LBD), or PD-related diseases. After measuring the D1R,
D2R, and D3R in postmortem LBD patients, we clarified
whether there were differences in DRs among these classi-
fications. We hope that further insights into these distinc-
tions will provide pathological references to aid the
diagnosis of PDD and DLB and help in the discovery of
new therapeutic targets for these diseases.
Methods
Tissue collection
Human brain tissue was collected after death from a total
of 21 control, 34 AD, 11 PD, 16 DLB, and 10 PDD cases
who were longitudinally assessed by clinical and patholog-
ical features. Most control and AD cases were obtained
from the Alzheimer Disease Research Center, while most
PD-related cases were obtained from the Movement
Disorders Center in the Department of Neurology, School
of Medicine, Washington University in St. Louis. Brain
removals were conducted after the written consent was
obtained from the next-of-kin and all procedures were
approved by the ADRC ethical committee and in accor-
dance with local ethical committee procedures and best
practices.
Quantitative autoradiograph
Brain tissue sections were made at 20 μm from the stria-
tum and SN separately. After removing endogenous
dopamine, sections were incubated with radiotracers
[3H]SCH23390, [3H]Raclopride, and [3H]WC-10 at a
concentration of 1.5 nmol/L, 4 nmol/L, and 4 nmol/L,
respectively. When treated with [3H]SCH23390 and [3H]
WC-10, 30 nmol/L of ketanserin and 10 nmol/L of
Way-100635 were used to block the off-target binding of
[3H]SCH23390 to 5-HT2 and [
3H]WC-10 to 5-HT1A,
respectively. Nonspecific binding was determined by
applying 1 µmol/L (+)-Butaclamol, 1 µmol/L S-(-)-eticlo-
pride, and 1 µmol/L S-(-)-eticlopride to block target
receptors of D1R, D2R, and D3R, respectively. After
incubation, slides were dried, made conductive, and
placed into a Beta Imager 2000Z (Biospace, France) to
collect autoradiograph images. Images were analyzed
using the Beta-Vision Plus (Biospace, France) software to
calculate receptor densities.
Determination of actual densities of D2 and
D3 receptors
It is hard to distinguish D2R and D3R from each other
because of the high degree of structural similarity between
the two receptors. Many studies have used raclopride as a
specific radiotracer for D2R, but this ligand is not able to
distinguish between D2R and D3R.3 This approach gives
a higher reading for D2R density than its actual density.
To provide more accurate data, we used a mathematical
model previously published by our team4 to calculate the
actual densities of D2R and D3R via quantitative autora-





where a1 and b1 are the fractional occupancies of [3H]
WC-10 to D2R and D3R. B1 is the apparent total recep-
tor density (both DR2 and D3R) measured directly from
the autoradiography experiment of [3H]WC-10 in human
brain tissues. Likewise, a2, b2, and B2 are the correspond-
ing parameters for [3H]Raclopride, respectively. a1, b1,
a2, and b2 can be readily calculated according to our
publication and their values are 0.05, 0.78, 0.71, and 0.19
respectively.
In situ hybridization & Immunohistochemistry
In situ hybridization (ISH) was performed on brain tis-
sue sections to examine the expression of D2R and
D3R mRNA according to the manufacturer’s protocol
(ACD Inc, CA). Results indicated tiny purple-reddish
granules in the striatum under optical microscopy. After
mRNA detection, some slides were blocked with 10%
BSA, incubated with the primary antibody (Abcam,
MA) for postsynaptic density protein 95 (PSD95), and
the corresponding secondary antibody (Sigma, CA).
Samples were labeled with a diaminobenzidine (DAB)
kit (ThermoFisher, TX), and counterstained with hema-
toxylin (Sigma, CA), and finally analyzed with Image J
software.
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Immunofluorescence (IF)
Brain tissue sections were blocked with 10% BSA, incu-
bated for 10 h with primary antibodies for D2R (Fisher,
MA), PSD95, and synaptophysin (Abcam, MA). Samples
were then incubated with Alexa 488, 546, or 647-conju-
gated donkey secondary antibodies (Life Technologies,
CA) to complex with the primary antibodies. Images of
the striatum regions were then acquired using fluores-
cence microscopy (LSM, Zeiss, German).
Statistical analysis
The receptor densities were calculated as described previ-
ously and expressed as fmol/mg tissue. If the data were
observed to be lower than 0 (often due to the negligible
D2R density), the data were considered to be 0. Data
were expressed as mean standard deviation (SD). A
one-way analysis of variance (ANOVA) was used to ana-
lyze the differences between various disease groups and
the Bonferroni method was used for post-hoc tests. A
survival curve was obtained by the Kaplan–Meier method.
All the statistical analyses were conducted using IBM
SPSS statistics 22.0 software.
Results
Physical, neuropathological, symptomatic,
and therapeutic features of all cases
All the cases involved a relatively elderly population. The
mean age at death showed that individuals in the PD and
PDD groups died earlier than the control group
(P < 0.05). The brain weight of AD patients was signifi-
cantly lower than that of the control, PD, and PDD groups
(P < 0.05). This change in brain mass is consistent with
the substantial neuronal cell loss and atrophy commonly
seen in AD. The neuropathologic evaluation revealed Braak
neurofibrillary tangle (NFT) scores of stage V or VI in
most of the AD patients, but only mild stages (I to III) in
most of the LBD cases. Control cases significantly differed
from the other groups on amyloid beta (Aβ) pathology
(P < 0.01). There were no statistical differences in the age
of onset between all groups. It is noteworthy that when dis-
cussing the symptomatic and therapeutic features – hallu-
cination, dyskinesia, PD stage, and dopamine
responsiveness – between PD, DLB, and PDD groups; we
used LBD cases obtained from the Movement Disorders
Center as the data received from the AD center had incon-
sistent evaluation criteria and incomplete data. The results
showed that there were no differences between PD, DLB,
and PDD groups with the symptomatic and therapeutic
features mentioned (Table 1).
Quantitative calculation of Dopamine D1,
D2, and D3 receptors in the striatum and SN
of each group
Dopamine D1 receptor
The calculated data show that there were no statistical
differences of D1R in the caudate (Cau) and putamen
(Put) between groups. The AD group showed a modestly
lower expression when compared with other groups but
this result was not statistically significant. D1R density
was lower in the SN than in the striatum in all groups,
but there were no differences between groups (Fig. 1A
and B).
Dopamine D2 receptor
The data obtained from the equations revealed that the
D2R distribution was quite different from the D1R distri-
bution. D2R expression in the Cau and Put of PD, DLB,
and PDD groups was significantly lower than in the con-
trol and AD groups (with P < 0.05). The PD, DLB, and
PDD groups showed no significant differences in the den-
sities of D2R in the Cau and Put. No obvious differences
were found in the SN of the different groups (Fig. 1C
and D).
Dopamine D3 receptor
The results showed that the PD, DLB, and PDD groups
had lower D3R expression in the Cau and Put than that
in the AD group. However only D3R densities in DLB
showed statistical differences compared with the AD
group (P < 0.05). A similar tendency was also found in
SN but without statistical significance (Fig. 1E and F).
All the data relating to D1R, D2R, and D3R densities in
the striatum and SN of each group are shown in
Table 2.
Analysis of D2R and D3R mRNA expression
in the striatum of each group
The expression of D2R and D3R mRNA were examined
using ISH and the results showed that D2R and D3R
mRNA only appeared in neurons located in the Cau and
Put but not in the internal capsule (green rectangle
Fig. 2A Con panel), demonstrating the reliability of our
results. Results showed that D2R mRNA expressions in
PD, DLB, and PDD groups were significantly lower than
in the control and AD groups (with P < 0.05, Fig. 2A).
D3R mRNA also showed reduced appearance in DLB
and PDD groups when compared with the AD group
(with P < 0.05, Fig. 2B).
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D2R expression showed more colocalization
with PSD95 which are not significantly
decreased
IF results showed that much of the D2R staining colocal-
ized with PSD 95, a postsynaptic protein, but the colocal-
ization with synaptophysin, a presynaptic protein, was
less frequent in the control and PD group (Fig. 2C).
Results between PD and control groups show only a
minor and not statistically different reduction in PSD95
expression (PSD95 density/per field) in the striatum
(Fig. 2D). No differences in cell densities (cell numbers/
per field) of the striatum were found between control and
PD groups (Fig. 2D).
Comparing the expression of D1R, D2R, and
D3R in different regions of all groups
We compared the expression of related DRs in different
regions in all groups (Figure 3A–C) and found a lower
density of D1R in the SN than in the Cau and Put in all
5 groups. D2R expression was greatly reduced in the SN
compared to the Cau and Put in control and AD groups.
However, these differences were not observed in PD,
DLB, and PDD groups. This is mainly due to the remark-
able decline of D2R in the Cau and Put in PD, DLB, and
PDD patients when compared with control and AD
patients. D3R in the SN was also statistically lower than
in the Cau and Put in AD, PD, and PDD groups
(P < 0.05). While similar results were also found in the
control and DLB groups but were not statistically signifi-
cant. It is important to note that DR densities were found
to be comparable in the Cau and Put in all these groups,
even at the individual patient level (data not shown).
Comparing the expression of different
dopamine receptors in the Cau, Put, and SN
region in all groups
We compared the expression of DRs in the related
regions of all five groups (Fig. 3D–F). There were no dif-
ferences between the three receptor densities in the
Table 1. Parts of the characteristics of the groups
Con AD PD DLB PDD P
Gender 11 Female/10 Male 20 Female/14 Male 3 Female/8 Male 7 Female/9 Male 2 Female/8 Male 0.145
Age at death(years old) 87.2  9.1 82.1  8.0 76.4  6.8 81.3  6.2 77.4  7.8 0.002
PMI(h) 15.4  12.0 13.7  6.3 14.9  10.4 17.2  9.7 11.2  5.6 0.522
Brain weight(g) 1259  174 1134  147 1298  120 1230  152 1325  176 0.001
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DLB(McKeith) criteria ------- ------ 2 no Lewy
bodies/1 diffuse type
10 diffuse type 7 diffuse type 0.000
Age onset(years old) ------ 71.3  10.3 63.8  8.4 67.7  9.7 62.9  9.7 0.066
Hallucination ------ ------ 3 no/7 yes 2 no/9 yes 0 no/9 yes 0.230
Dyskinesia ------ ------ 4 no/6 yes 4 no/7 yes 3 no/ 1 modest/5
yes
0.986
PD stage ------ ------ 3 stage2/1 stage 2.5/
4 stage3/2 stage4
2 stage2.5/3 stage 3/
4 stage4/2 stage5
2 stage2/3 stage 3/
3 stage4/1 stage5
0.143
L-Dopa responsiveness ------ ------ 1 modest/9 yes 1 no/1 modest/9 yes 2 modest/7 yes 0.721
Italic for p-value indicates P < 0.05. If the total number of different levels of pathological criteria is less than the total number of cases, then some
patients have not been diagnosed according to the pathological criteria.
PMI = postmortem interval, NIA-Reagan criteria were divided into four levels: high, intermediate, low likelihood of dementia, and criteria not met.
Braak NFT = Braak neurofibrillary tangle stage, ranging from stage I to VI with increasing histopathologic manifestations. Braak AB stage = Braak
amyloid-beta plaque stage, ranging from stage A to C with increasing histopathologic manifestations. DLB criteria were used to indicate the pres-
ence and distribution of Lewy body related pathology, including brainstem predominant type, intermediate or transitional type, diffuse type, or no
Lewy bodies. Hallucination and dyskinesia denote there is accompanying hallucination or dyskinesia in PD patients. Dopamine responsiveness
denotes whether the patients are responsive to L-Dopa treatment. No report shown with “------”.
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Figure 1. Quantitative autoradiographic analysis of D1R, D2R, and D3R densities in the striatum and SN of all groups. (A) Autoradiograms of
specific and nonspecific binding of [3H]SCH23390 in the striatum (upper panel) and SN (lower panel) of all groups. (B) Quantitative analysis of
D1R densities among all groups. (C) Autoradiograms of specific and nonspecific binding of [3H]Raclopride in the striatum (upper panel) and SN
(lower panel) of all groups. (D) Quantitative analysis of D2R densities among all groups. (E) Autoradiograms of specific and nonspecific binding of
[3H]WC-10 in the striatum (upper panel) and SN (lower panel) of all groups. (F) Quantitative analysis of D3R densities among all groups.
*P < 0.05 versus Con, #P < 0.05 versus AD.
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striatum of the control group. D1R was found to be
lower than D2R and D3R in the striatum of the AD
group. While D2R showed remarkably lower expression
in the striatum of the PD, DLB, and PDD groups – these
results were found to be statistically significant (P < 0.05)
when compared with D1R and D3R, with the exception
being the Cau of the DLB group. D3R was consistently
significantly higher (P < 0.05) in SN compared to D1R
and D2R in all groups.
Correlation between DRs densities with PD
associated symptomatic and therapeutic
features
We found slight differences in receptors densities between
Cau and Put. These measurements were averaged to
reduce noise for a whole striatal measurement. We then
evaluated the correlation between striatal and SN DR
densities with PD associated clinical manifestations: age
of onset, hallucination, dyskinesia, and PD stage. We also
correlated DR densities with PD associated therapeutic
features: dopamine responsiveness and survival time. The
results show that most features have a closer correlation
with receptors densities in the striatum than in the SN
(Table 3). Striatal D1R density significantly correlated
with dopamine responsiveness, whereas striatal D3R den-
sity correlated with survival time. The combination of
striatal D1R and D3R (D1R + D3R) closely correlated
with age of onset, PD stage, dopamine responsiveness,
and survival time (Fig. 4A). These findings suggest that
when these receptors are analyzed together, D1R + D3R
may relate to these symptomatic and therapeutic features
more strongly than when analyzed individually.
Impact of D1R and D3R densities on overall
survival
We arbitrarily divided the PD patients into three groups
according to their receptor densities and performed
Kaplan–Meier survival analysis to reveal the impact of
receptors densities on the overall survival rate. The results
revealed that D3R grade (χ2 = 8.700) and D1R + D3R
grade (χ2 = 11.217) in the striatum correlated with the
overall survival rate much better than did D1R grade
(χ2 = 1.767). The survival rate also showed significant
differences in high, medium, and low D1R + D3R densi-
ties (P < 0.01) (Fig. 4B).
Discussion
It has been widely documented that the densities of D1R,
D2R, and D3R may change in PD patients and that these
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Figure 2. In situ hybridization (ISH) analysis of D2R and D3R mRNA and the combination of ISH with immunohistochemistry (IHC) of PSD95 in
the striatum of control and PD groups. (A) ISH analysis of D2R mRNA in the striatum of all groups. (B) ISH analysis of D3R mRNA in the striatum
of all groups. (C) Localization of D2R expression in the synapse indicated by postsynaptic protein PSD95 and presynaptic protein synaptophysin.
(D) Combined ISH with IHC to indicated the expression of D2R mRNA and PSD95. *P < 0.05 versus Con, #P < 0.05 versus AD.
230 ª 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association
D1R+D3R Correlates with PD Clinical Features P. Yang et al.
features of treatment. Subsequently, it is of great impor-
tance to understand the differences in these receptors
between control, AD, and LBD patients. However, the
results of early studies on this subject are often inconsis-
tent. There might be several reasons for these inconsisten-
cies. For one, early studies often used different species of
animals, but rarely used human specimens. Furthermore,
as D2R and D3R share 79% sequence homology, it is
hard to distinguish D2R from D3R using conventional
methods such as PET due to the lacking of selective D2R
or D3R radiotracers. Most studies investigating D2R used
raclopride to identify the receptors, but these studies fail
to reconcile the fact that raclopride binds to D2R and
D3R3, which in turn inflates the values for D2R density.
In this study, we used the mathematical model previously
developed by our group to measure the densities of D2R
and D3R in a large cohort of control, AD, PD, DLB, and
PDD brains. Our results and observations lead us to some
main ideas that we would like to assert.
Loss of D2R may play an important role in
PD pathogenesis
D2R was considered to be greatly involved in PD for a
long time. Mice with a D2R deficiency5 or treated with
antisense oligodeoxynucleotides for D2R6 show abnormal-
ities in motor activity analogous to symptoms presented
in PD such as reduced locomotion and slow and uncoor-
dinated movements. Further, elevated D2R expression was
reported to be neuron protective7 and benefit motor per-
formance in MPTP-induced PD mice8, and alleviate
symptoms in PD patients.9 Several D2R agonists have
been used in PD interventions: pramipexole, ropinirole,
apomorphine, and rotigotine.9
Our results indicated that there is a significant decrease
in D2R expression in LBD patients when compared with
control and AD patients (about 15.9% and 18.83% of
non-PD subjects expression in the Cau and Put), which
we considered an important feature of elder PD patients.
Figure 3. Comparison of the expression of DRs in the different regions of all groups. (A) Quantitative analysis of D1R in the Cau, Put, and SN of
all groups. (B) Quantitative analysis of D2R in the Cau, Put, and SN of all groups. (C) Quantitative analysis of D3R in the Cau, Put, and SN of all
groups. *p < 0.05 versus Cau, #p < 0.05 versus Put. (D) Quantitative analysis of different dopamine receptors in the Cau of all groups. (E)
Quantitative analysis of different dopamine receptors in the Put of all groups. (F) Quantitative analysis of different dopamine receptors in the SN
of all groups. *P < 0.05 versus D1R, #P < 0.05 versus D2R.
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The D2R mRNA expression significantly reduced in the
striatum of PD patients, but the reductions are lesser than
seen in the receptor autoradiography studies. A reason for
this discrepancy may be that the protein level is not
always proportional to the mRNA expression, since pro-
tein translation from mRNA may be attenuated in PD
brains,10 but this warrants further investigations. The
reduction in D2R expression from this study is similar to
Farkas’s study where the binding of [3H]raclopride, which
has 11.25 folds preferential binding to D2R than D3R, in
PD postmortem putamen is ~ 8% of the control group
(PD 3.73  0.07, control 47.97  10.00 fmol/g).11 Our
results and data from Farkas showed a much lower
expression of D2R in PD than reported by others. The
low D2R density may result from the high age of our
subjects. Several studies show that D2R expression
decreases at high age, after a prolonged course of PD, as
the disease progresses, or under chronic exposure to
dopamine agonists. Striatal D2R mRNA and protein
expressions were about 50% in aged rats (18- to 20-
month-old) in comparison to young adult rats (10-week-
old).12 However, the rats’ age in the study was 18 months
or equivalent to 45 years of human age, they are much
younger than our patient for valid comparisons.13 One
clinical PET study indicated that D2R binding is signifi-
cantly reduced in the Cau and Put after 3–5 years of PD
progression, estimates of this decline are 0.6% per year in
healthy subjects and 1.8 to 3% in PD patients.14 One
study found that PD patients with more serious symp-
toms (at H&Y stage III and IV) have significantly lower
levels of D2R than those with mild symptoms.15 A further
report indicates that dopaminergic treatment for PD
patients induces D2R reductions of 19.0% and 23.5% in
the Cau and Put, respectively, as measured by [11C]raclo-
pride.16 The longer PD duration, more severe disease
stage, and higher age may be the reason why the patients
in our study had much lower D2R densities.
IF showed that the D2R expression located primarily in
the postsynaptic neurons, and the reduction in D2R may
not be related to the post synapse neuronal loss in the
striatum of PD patients, as we found that the density of
postsynaptic protein PSD95 has only a slight decrease in
PD group (without statistical significance). And the stria-
tum is not considered the brain region where neuron loss
occurs in PD.17 The significant decrease of D2R in the
striatum of PD patients supports that aging is a promi-
nent risk factor for PD.12 Our findings may also explain
why D2R agonists are promising dopaminergic monother-
apy in early-stage PD but not in advanced-stage PD
patients.18 Although we have shown that decreased D2R
may be an important cause of PD in elder people, the
uncertainty of this finding in young cohorts remains to
be investigated. The change of PSD95 in PD is still in
controversy, both an increase19 and a decrease of PSD95
in PD models20 have been reported.
D1R and D3R play important roles in PD
treatment, progression, and survival
Although most DR agonists used in PD are designed for
D2R activation,21 and D2R is thought to be the main
dopamine therapy target.18 Other receptors such as D1R
and D3R may also be involved as DR agonists showed
reduced neuroprotective effects throughout treatment but
the loss of all protective effects was not seen when D2R
was knocked out.22 It has long been accepted that
decreases in D1R density are directly correlated with PD
symptoms23 and the increased striatal D1R density is a
critical indicator for DR agonists’ clinical sensitivity.24
While D3R is reported to be decreased in drug-naive PD
Table 3. Correlation between D1R and D3R with symptomatic and therapeutic features in Striatum of PD-associated disease
Striatum SN
D1R D3R D1R + D3R D1R D3R D1R + D3R
Age on onset Coefficient −0.347 −0.240 −0.450* −0.071 0.464* 0.449*
Sig. 0.076 0.229 0.024 0.719 0.026 0.032
Hallucination Coefficient 0.092 0.049 0.207 −0.211 −0.023 −0.111
Sig. 0.648 0.809 0.320 0.281 0.916 0.615
dyskinesia Coefficient 0.196 −0.073 0.211 −0.183 −0.410 −0.392
Sig. 0.327 0.719 0.311 0.351 0.052 0.064
PD stage Coefficient 0.362 0.224 0.493* −0.242 −0.069 −0.156
Sig. 0.064 0.262 0.012 0.216 0.755 0.477
Dopamine responsiveness Coefficient 0.415* 0.134 0.399* 0.153 −0.290 −0.203
Sig. 0.031 0.506 0.048 0.436 0.179 0.353
Survival time Coefficient 0.327 0.450* 0.422* −0.073 −0.266 −0.289
Sig. 0.096 0.019 0.036 0.713 0.220 0.181
Sig., Significance; Coefficient, Pearson correlation coefficient.
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patients25 and considered as a potential target for PD
intervention.21 A D1R preferential agonist, dihydrexidine
(with D1R:D2R 10 fold selectivity), was reported to atten-
uate parkinsonian that can be blunted by a D1R antago-
nist in a rat PD model.26 One double-blind and
randomized study indicated that a selective D1R ago-
nist, ABT431, led to a full antiparkinsonian response in
advanced PD patients.27 D3R activation is also reported
to alleviate striatal DA depletion and behavioral deficits
in PD mice, and these effects are D3R dependent as the
protective effect disappeared in D3R-/- mice or mice with
D3R antagonist pretreatment.28,29 D3R preferential ago-
nists are also proven to be effective, and show a dose–de-
pendent response, in alleviating the symptoms of PD
advanced patients.30,31
The protective effects of D1R or D3R activation on PD
symptoms may be independent of D2R or play a coopera-
tive/synergistic effect with D2R. D1R-/- and D2R-/- mice
showed comparable reductions in locomotion, while
D1R-/-D2R+/- mice showed more severe impairment in
locomotive activity.32 Further, microinjections of D1R
and D2R agonists cocktails in the striatum of PD mice
have produced a better motor stimulating effect than that
produced by D2R agonist alone.33 These results underline
the importance of D1Rs and D2Rs in coordinating move-
ments. Similar results were also observed between D2R
and D3R. D2R-/-D3R-/- mice showed qualitatively similar
but significantly more severe behavioral symptoms than
D2R-/- mice.34 While the use of the D2R/D3R agonists
showed more improvements to PD symptoms in rats with
striatal overexpression of both D2R and D3R than the
improvement in those with D2R alone.35 Together, these
studies indicate that D1R and D3R might be potential
targets for alleviating PD symptoms in late-stage PD
patients with reduced D2R expression.
The synergistic effect between D1R and D3R
We conducted correlation analyses between D1R, D2R,
D3R, D1R + D2R, D1R + D3R, D2R + D3R, D1R +
Figure 4. Relationship between D1R + D3R density in the striatum with PD associated symptomatic and therapeutic features. (A) Linear
regression analysis between D1R + D3R in the striatum with the age of onset, PD stage, dopamine responsiveness, and survival time are shown
with R2 values of 0.160, 0.243, 0.203, and 0.178, respectively. (B) Kaplan–Meier survival curves of D1R, D3R, and D1R + D3R made with low,
medium, and high-density levels.
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D2R+D3R, D1R/D3R, and D1R-D3R in the striatum
with symptomatic and therapeutic features in all LBD
patients (not all data are shown in Table 3). Only D1R,
D3R, and D1R + D3R showed a statistically significant
relationship with these features (P < 0.05). D1R and D3R
each showed a close correlation with one of the six clini-
cal features. D1R + D3R showed a close correlation with
four of the six clinical features: age of onset, PD stage,
dopamine responsiveness, and survival time. This correla-
tion suggests that D1R + D3R might be a better biomar-
ker for LBD features. The synergistic effect between D1R
and D3R has been shown both behaviorally and biochem-
ically in previous reports,36 but the question remains,
how do D1R and D3R synergize?
(1) Synergism between D1R and D3R may lie in het-
eromers
D3R shows a great impact on the neuronal regulation
of D1R, and vice versa. D3R could enhance the density of
D1R by down-regulating the internalization of D1R,37
and then forming a D1R-D3R heteromer, which enhances
the affinity of D1R to DA or associated agonists when
compared to native state D1R.38,39 Moreover D3R helps
activate the downstream signal pathway of D1R and
increases its sensitivity.40 These impacts of D3R on D1R
may lead to their synergistic effect. Furthermore, D1R
may also enhance D3R expression. The expression of both
D3R mRNA and protein in the striatum can be upregu-
lated by repeated D1R stimulation. While this induction
can be prevented by SCH23390 (D1R antagonist), but
mimicked by SKF39393 (D1R agonist).41,42 In this way,
D1R promotes D3R expression while D3R results in the
oversensitivity of D1R, which may lead to the enhanced
physiological effect of both D1R and D3R, and eventually
cause that the density of D1R + D3R being more related
to the symptomatic and therapeutic features in PD (Fig. 5
A).
(2) Synergism between D1R and D3R may lie in the
alleviation of pathological injuries or augment of protec-
tive effects
Although most of the studies discussing the synergistic
effect via the direct formation of D1R-D3R heteromers,
this hypothesis is in debate as D1R and D2R are mostly
segregated in the direct and indirect medium spiny neu-
rons (MSNs),33 hinting other synergistic effects may exist
such as the alleviation of oxidative stress,43–45 the promo-
tion of Brain-derived neurotrophic factor (BDNF) expres-
sion,46,47 the elimination of neuroinflammation,48,49
increase of neurogenesis,50,51 and enhanced the number
of dopaminergic neurons and primary dendrites to exert
neurotrophic effects.52,53 The proposed synergistic effects
of D1R and D3R are summarized in Figure 5B.
Previous reports have suggested that D1R or D3R
density might be a predictive indicator for the
diagnosis, treatment, or prognosis of PD patients. For
example, D1R and D3R expression is proved to be aug-
mented as early as 10–15 weeks before Parkinsonian
symptoms in DJ-1 knockout rat PD models.54 Other
results obtained from both patients and PD models
suggested that a high expression of the D3R gene in
the blood is specific for the preclinical staging and
therefore be recommended to be used for early diagno-
sis of PD.55 Some reports also suggested that a block-
ade of dopamine to D1R could decrease L-Dopa
responsiveness56 and the insufficiency of D3R closely
correlates with damage in respondence to dopaminergic
therapy.57 In this study, we found the combined density
of D1R + D3R in the striatum is more closely corre-
lated to clinical manifestations of LBD patients than
D1R or D3R separately.
Another question lies in why D2R agonists help alle-
viate clinical symptoms but much lower levels of D2R
were observed in elderly PD patients in this study.
Yet, it should be considered that DR agonists com-
monly used in clinical applications possess strong D1R
and/or D3R activation. Among DR agonists there are
two derivatives, ergoline and non-ergoline. Apomor-
phine, an ergoline derivative, once considered as D1R/
D2R agonist, has been subsequently proved to be a
D3R preferring agonist.58 Among the non-ergoline
derivatives: pramipexole, ropinirole, and rontigotine
are the most widely used dopamine agonists.
Pramipexole is considered to be a D1R/D2R/D3R ago-
nist.59 Ropinirole and rotigotine, first reported as
D2Rs agonists, were also found to bind D3R with
higher affinity than D2R.60
This is the first report in which D1R + D3R density is
more useful in predicting clinical manifestations of LBD
patients than D1R or D3R alone. The advantages of our
research lie in the fact that we used postmortem brains
and a validated method to calculate D2R and D3R. How-
ever, the patients selected in our experiment endured a
long disease course, had been treated with various drugs
for differing periods, and died for distinct reasons. There-
fore, our results need to be further validated by clinical
trials or animal models.
In conclusion, we observed that D2R densities are sig-
nificantly decreased in the striatum of later stage LBD
patients when compared with control and AD patients.
However, there are no significant differences in the den-
sity of DRs in the SN among these groups. Ultimately, we
believe that the evidence presented has shown that D1R +
D3R density may be a more proper influencing factor on
the PD features than D1R or D3R alone. Therefore, to
design the best individualized intervention, we need to
systematically measure the densities of D1R, D2R, and
D3R in the striatum.
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